GlassScriptPhysician profile
Robert Keith Dawson
NPI 1588727895
$2,190.00
in general payments reported to CMS, 2019-2025
21 companies · $734 in 2025
The $734 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $395 · 2022: $312 · 2023: $329 · 2024: $421 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,341 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,340.98 |
| Education | $142.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $823.56 | 2021-2025 | |
| Gilead Sciences, INC. | $203.63 | 2021-2025 | |
| Axsome Therapeutics, INC. | $191.60 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $172.66 | 2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $122.66 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $122.04 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Bayer Healthcare Pharmaceuticals INC. | $101.21 | 2021-2022 | |
| Lilly USA, LLC | $91.41 | 2021-2023 | Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.83 | 2023-2024 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $66.18 | 2024-2025 | Airsupra |
| Sunovion Pharmaceuticals INC. | $41.15 | 2021 | |
| Dexcom, INC. | $31.74 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $29.41 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Alkermes, INC. | $21.79 | 2023 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $19.92 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.12 | 2024 | Repatha, Otezla |
| Supernus Pharmaceuticals, INC. | $15.61 | 2025 | Qelbree |
| Eisai INC. | $15.17 | 2021 | |
| Organon LLC | $11.97 | 2022 | |
| Phathom Pharmaceuticals, INC. | $11.34 | 2025 | Voquezna |
| Corium, LLC | $6.00 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.